News
gla_wpadmin  

More Moderna vaccine for ‘Booster’ – limit for Biontech

Friday, 11/19/2021 6:28 PM from

dpa-AFX

| Views: 392

Vaccinations are possible nowadays against many diseases. (Symbol picture) ©

BERLIN (dpa-AFX) – The Corona booster vaccinations should increase significantly and strengthened with the vaccine from Moderna instead of Biontech be made. The Federal Ministry of Health emphasized on Friday that enough vaccine for such “boosters” would be available by the end of the year. Since the preparation from Biontech has so far made up more than 90 percent of orders, Moderna should be used more and more. This should ensure that sufficient vaccine is available in the short term. In addition, stored Moderna cans expired from the middle of the first quarter of 2022, but this must be avoided.

For Biontech, “maximum order quantities” are to be defined, as stated in a letter from the ministry to the federal states. First, the editorial network Germany reported (Saturday) about it. For the time being, practices should be able to order a maximum of 30 doses per week, vaccination centers and mobile vaccination teams 1020 doses. “Orders for Moderna vaccine are not subject to a maximum limit and are fully supplied,” says the letter, which is also available to the German press agency.

In the practices, due to the limitation in Biontech orders from November 23rd, a significantly increased need for advice can be expected, said the National Association of Statutory Health Insurance Physicians (KBV). “As a result, most of the patients who were vaccinated with Biontech as part of their basic immunization will now – if they are over 30 years old – receive a booster vaccination with Moderna,” said KBV Vice-President Stephan Hofmeister.

advertising

Further up?

HSBC Trinkaus & Burkhardt AG

The base prospectus as well as the final terms and the key information sheets are available here: TT95ZV,TT8SG4,. Also note the further notes to this advertisement. The issuer is entitled to terminate securities with an open-end term. You can find license information here.

advertising

Subscribe to more news for free

Note:
ARIVA.DE publishes analyzes, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been recognized by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” mark below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Other users were also interested in this article:

Reference-www.ariva.de

Leave A Comment